ARVN - Citi downgrades Arvinas to neutral cites valuation
2024-02-14 15:55:46 ET
More on Arvinas
- Arvinas: Positive Breast Cancer Data Leads To Other Developments
- Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
- Pfizer, Arvinas' breast cancer therapy gets FDA fast track status
- Arvinas draws Buy at Goldman Sachs on breast cancer therapy
- Seeking Alpha’s Quant Rating on Arvinas